Cargando…

Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial

BACKGROUND: In Japan, transarterial infusion chemotherapy using cisplatin (CDDP-TAI) is frequently used for advanced hepatocellular carcinoma (HCC). Moreover, oral chemotherapy with S-1, an oral fluoropyrimidine derivative, has also elicited promising responses in HCC patients. We determined the rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terazawa, Tetsuji, Kondo, Shunsuke, Hosoi, Hiroko, Morizane, Chigusa, Shimizu, Satoshi, Mitsunaga, Shuichi, Ikeda, Masafumi, Ueno, Hideki, Okusaka, Takuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011764/ https://www.ncbi.nlm.nih.gov/pubmed/24779747 http://dx.doi.org/10.1186/1471-2407-14-301

Ejemplares similares

A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Sasaki, Mitsuhito, et al.
Publicado: (2021)

Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma
por: Hagihara, Atsushi, et al.
Publicado: (2014)

A retrospective analysis of factors associated with selection of end-of-life care and actual place of death for patients with cancer
por: Kondo, Shunsuke, et al.
Publicado: (2014)

Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma
por: Kondo, Shunsuke, et al.
Publicado: (2018)

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma
por: Shiba, Satoshi, et al.
Publicado: (2012)

Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

Germline mutations in cancer-predisposition genes in patients with biliary tract cancer
por: Terashima, Takeshi, et al.
Publicado: (2019)

Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy
por: Kondo, Shunsuke, et al.
Publicado: (2012)

Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study
por: Iizumi, Sakura, et al.
Publicado: (2019)

The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives
por: Hijioka, Susumu, et al.
Publicado: (2021)

Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis
por: Mayahara, Hiroshi, et al.
Publicado: (2012)

Clinical characteristics of pancreatic and biliary tract cancers associated with Lynch syndrome
por: Takamizawa, Shigemasa, et al.
Publicado: (2021)

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials
por: Koyama, Takafumi, et al.
Publicado: (2019)

Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial
por: Morizane, Chigusa, et al.
Publicado: (2022)

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
por: Kudo, Masatoshi, et al.
Publicado: (2022)

Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment
por: Okusaka, Takuji, et al.
Publicado: (2016)

Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial
por: Ito, Tetsuhide, et al.
Publicado: (2012)

Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future
por: Ikeda, Masafumi, et al.
Publicado: (2015)

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
por: Ikeda, M., et al.
Publicado: (2016)

Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma
por: Kondo, S, et al.
Publicado: (2013)

Correction: The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry
por: Satake, Tomoyuki, et al.
Publicado: (2022)

The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin
por: Yoo, Sun Hong, et al.
Publicado: (2020)

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2018)

Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
por: Ikeda, Masafumi, et al.
Publicado: (2017)

Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment
por: Suyama, Koichi, et al.
Publicado: (2013)

Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreaticobiliary Cancer Aiming for a Comprehensive Genome Profile
por: Hijioka, Susumu, et al.
Publicado: (2023)

Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis
por: Okusaka, Takuji, et al.
Publicado: (2023)

Immunotherapy for hepatocellular carcinoma: current status and future perspectives
por: Okusaka, Takuji, et al.
Publicado: (2018)

Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy
por: Suzuki, Yuko, et al.
Publicado: (2018)

Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma
por: Guo, Jian-Hai, et al.
Publicado: (2020)

Phase II study of S-1 in patients with advanced biliary tract cancer
por: Ueno, H, et al.
Publicado: (2004)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
por: Ueno, Makoto, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9p5crvn5dlff09lkvgo46ss15l